Article
Trends in Clinical Development for PD-1/PD-L1 Inhibitors
Article reprint from Nature Reviews Drug Discovery
Apr 17, 2020
Download

This March 2020 article in Nature Reviews Drug Discovery outlines trends in the current landscape of clinical trials evaluating PD-1/PD-L1-targeted monoclonal antibodies, which are now the standard of care for 16 different types of cancer and tissue-agnostic indications. IQVIA and Cancer Research Institute collaborated on the analyses and report.

Related solutions

Contact Us